期刊文献+

The advancement of immunotherapy in hepatocellular carcinoma 被引量:1

原文传递
导出
摘要 Most patients diagnosed with hepatocellular carcinoma(HCC)present with advanced or metastatic disease.The lack of therapeutic options in the treatment of advanced HCC accounts for its high mortality and recurrence rate.HCC is known as an immunogenic tumor,which develops in chronically inflamed livers.Anti-PD-1/PD-L1 antibodies(immune checkpoint inhibitors,ICB)were approved by the FDA to treat advanced HCC in patients previously treated with sorafenib as a second line.This has opened up a new era of anticancer treatment,although the response rate of HCC to anti-PD-1/PD-L1 antibodies is only around 20%.Other than ICB treatment,adoptive cell transfer,dendritic cell-based vaccines and oncolytic therapy are currently under clinical trials.In this review,different immunotherapy approaches for HCC is presented.Current knowledge on the mechanisms of action for each approach is discussed and relevant,ongoing clinical trials are presented.We also discuss the future of immunotherapy and combination treatment for HCC patients.
出处 《Hepatoma Research》 2020年第5期61-72,共12页 肝癌研究(英文版)
基金 This work was supported by grants from Beijing Municipal Science and Technology(Grant No.Z181100001318007) National Natural Science Foundation of China(NSFC)(Grant No.31991173).
  • 相关文献

参考文献1

共引文献13

同被引文献3

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部